Mine Yuichi, Munir Hafsa, Nakanishi Yoichi, Sugiyama Daisuke
Department of Research and Development of Next Generation Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan Center for Clinical and Translational Research, Kyushu University, Fukuoka, Japan
Department of Research and Development of Next Generation Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.
Anticancer Res. 2016 Jul;36(7):3565-70.
Cancer remains one of the leading causes of death worldwide, indicating that current cancer therapies are ineffective. Therefore, new treatments with high specificity and low toxicity are needed. Cancerous cells can be distinguished from normal cells based on expression of key proteins, namely surface proteins, scaffold proteins and signaling molecules. Moreover, cancer cells communicate with the tumor microenvironment consisting of a heterogenous population of cells, extracellular matrix components and soluble factors such as cytokines/chemokines and growth factors. Most therapeutic interventions have been designed to specifically target these proteins of interest. Biomimetic peptides (BPs) are artificially designed peptides that imitate the action of parent proteins or peptides. BPs can be classified into at least three types based on their target molecule: BPs that target (i) cell-surface molecules, (ii) intracellular molecules, and (iii) cancer cell-tumor microenvironment interactions. In this review, we analyze/discuss the current strategies for targeting tumors using BPs.
癌症仍然是全球主要的死亡原因之一,这表明目前的癌症治疗方法效果不佳。因此,需要高特异性和低毒性的新治疗方法。癌细胞可以根据关键蛋白质的表达与正常细胞区分开来,这些关键蛋白质即表面蛋白、支架蛋白和信号分子。此外,癌细胞与由异质细胞群体、细胞外基质成分以及细胞因子/趋化因子和生长因子等可溶性因子组成的肿瘤微环境进行通信。大多数治疗干预措施都旨在特异性地靶向这些感兴趣的蛋白质。仿生肽(BPs)是人工设计的肽,可模仿母体蛋白质或肽的作用。根据其靶分子,BPs可至少分为三种类型:靶向(i)细胞表面分子、(ii)细胞内分子以及(iii)癌细胞-肿瘤微环境相互作用的BPs。在本综述中,我们分析/讨论了使用BPs靶向肿瘤的当前策略。